Skip to content

Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2

April 19, 2010

Breast Cancer Prevention: Raloxifene as Effective as Tamoxifen with Fewer Side Effects

Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Full results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention are discussed in this press conference by a panel of experts.

Download the teleconference (29.3 MB file; 42:41 minutes duration. Requires QuickTime).

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 62 other followers

%d bloggers like this: